Can a smaller dose of a drug ease the pain of pregnancy loss?
NCT ID NCT06909123
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of cabergoline can safely prevent lactation and breast discomfort after second-trimester abortion or pregnancy loss. The standard dose works but can be costly and cause side effects. Researchers will enroll 36 people to compare the reduced dose with the usual dose, using blood tests and symptom surveys.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cabergoline (Dostinex)
- What this could lead to
- If successful, this could provide a cheaper, more tolerable option to prevent breast pain and milk production after second-trimester pregnancy loss or abortion.
- What could go wrong
- This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The reduced dose might be less effective at stopping lactation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pregnant people, ages 18 years or older * Intrauterine pregnancy between 16/0-25/6 weeks of gestation age (by ultrasound dating performed prior to or same day of enrollment visit) * Consented for an induced, elective abortion or undergoing management of fetal demise * English or Spanish speaking * Able to consent for a research study, literate in English or Spanish * Willing to comply with study procedures and follow-up * Access to smart phone throughout study Exclusion Criteria: * Prior mastectomy (breast reduction or chest masculinization surgery acceptable) * Currently breastfeeding * Currently receiving dopamine agonist or antagonist therapy for other indication leg syndrome) * Contraindication to cabergoline (as per package insert) * Uncontrolled hypertension - defined as baseline BP \> 160/110, or chronic hypertension requiring more than one baseline medication, or current pregnancy-induced hypertension spectrum disorders (gestational hypertension, preeclampsia, eclampsia) * History of cardiac valvular disorders or valvular repair * History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lactation suppressed are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.